DCAL - READY TO SOAR - A buy on DIP stockAGAINNNNNN....
with a big OPPORTUNITY in DISHMAN CARBOGEN AMCIS LTD🚀🚀
This stock has completed its correction and it's now ready to move towards north. let see how?
Technical view- a simple understanding for beginners
* The stock has given a breakout with good intensity of volume .
* The price changed its structure from lower low to higher high
* Stock price is challenging Upper Bollinger Band
* RSI ( a strength indicator) is above 60 in Daily Time Frame which indicates strong momentum
Understanding Waves
Key Elliott Wave Principles:
1. Five-Wave Impulse Pattern : The primary trend unfolds in five waves (1-2-3-4-5). Waves 1, 3, and 5 move in the direction of the trend, while waves 2 and 4 are corrective.
2. Three-Wave Corrective Pattern: After a five-wave sequence, a correction typically follows, consisting of three waves (A-B-C) that move against the primary trend.
3. Wave Relationships: Fibonacci ratios play a crucial role in Elliott Wave analysis, often governing the length of the waves.
4. Wave Characteristics: Each wave has its own set of characteristics. For example, Wave 3 is usually the most powerful, showing the strongest price movement, while Wave 5 may signal the final push before a significant correction.
Current Elliott Wave Analysis on DCAL
- The stock is currently in bigger IMPULSE Wave in which it has completed wave 1 and wave 2 (correction) now it is in the bigger and the strongest wave 3
Targets - generally the targets of wave 3 goes up to 1.618 levels with TREND FIB from wave 1 to wave 2
* In this stock, the targets as per wave theory is around 425.70
* Intermediate targets as per technical view are 247-290-375-425.70
Invalidation / stoploss - invalidation of the up-move is 80
Trade Plan-
* one can add at current levels and again if it comes down you will get an opportunity to add more till 150-140
* Invest keeping in mind for short to long term view, not for speculation.
THANK YOU
KARANN DINGRA
Breakoutstocks
ALB & GPN's Reversal Breakout Could Spark Significant GainsAlbemarle Corporation NYSE:ALB
● On the monthly chart, the stock is bouncing back from a long-standing trendline support that has held firm over the years.
● The daily chart reveals the emergence of an Inverted Head & Shoulders pattern following a significant decline.
● With a recent breakout, the stock appears poised for a potential trend reversal.
● Traders should keep a close eye on this stock for potential buying opportunities.
Global Payments NYSE:GPN
● The stock has formed a Double Bottom pattern after a brief period of consolidation.
● Recently, the price broke out from this formation and has been maintaining its position above the breakout point.
● The price movement suggests a short-term buying opportunity, as the resistance level is quite distant from the current price.
Nippon India Nippon India is seen following 6 week down trendline and we have fresh Trendline breakout above 680,
also stock is trading above 20, 50, 100 and 200 EMA.
Stock bounced back from 20 EMA on weekly time frame
This stock can hit all time high in 2-3 weeks as per my analysis. Looking for 810, then 925 in 5-6 months.
Stock is having strong support at 640.
This is not a buy recommandation.
ASKAUTO strengthening Financias as well as Price Action NSE:ASKAUTOLTD
........................
KEY Performance
........................
Robust growth in both top line & bottom line
Highest ever Revenue & PAT in any quarter in past
Revenue growth outperformed Industry growth
Revenue up +31%, EBITDA up + 59%, PAT up +63%
EBITDA Margins at 11.9%, up 210 bps YoY
EBITDA margin improvement resulting from:
Higher Volume driven economies of scale
Benefit from ramp up of Karoli facility
Focus on cost optimization initiatives
EPS at Rs. 2.88, up +63% YoY
CRISIL revised outlook to Positive from Stable
CRISIL reaffirmed Credit Rating to AA- for
Long Term and A1+ for Short Term
Construction work of new Bengaluru Plant
progressing well as per plan
......................
Powertrain Agnostic product offerings in both EV and Non-EV.
4 World Class Technical Collaborations and 2 World Class Joint Ventures.
Robust financial performance with 17% Revenue growth, 26% EBITDA growth, 41% PAT growth and RoACE of 23.64% in FY24.
High entry barriers due to proprietary material formulations, in-house Engg, Designing & Tool room.
Long standing relationship with customers & established Aftermarket focused on Quality, Cost & Delivery.
ALLCARGO Logistics are Stablishing and Sustaining in PerformanceNSE:ALLCARGO
...................................................................................................................................................................................................................................................................................................................................................
KEY BUSSINESS HIGHLIGHTS
Global events coupled with high demand across trade lanes during the second quarter of 2024 (calendar year) has led toimproved volumes and increased freight rates. Demand is expected to continue through the peak season till end of theyear.
LCL volume for the quarter ended June’24 stood at 2.25 million CBM, similar on YoY basis and representing a QoQ growth of6%. FCL volume for the quarter stood at 156K TEUs, similar to last quarter and up 9% on a YoY basis.
ECU Worldwide onboarded a new leadership team in Argentina, Uruguay and Paraguay as part of growth initiatives in LatinAmerica.
Contract Logistics business has reported a revenue growth of 13% on a QoQ basis and 22% on a YoY basis on the back ofincreased wallet share from existing clients.
Express Business: Operating cost continues to get optimized to bring about future growth in EBITDA. For Q1FY25 EBITDAstood at Rs. 20 crores, up 11% YoY and 33% on QoQ basis
...................................................................................................................................................................................................................................................................................................................................................
Supply chain market is estimated to be at ₹63,000
crores.
• ASCPL is a leading pan india 3PL player with an
expansive network
• Market leadership in chemical warehousing and
dominance in western India
• Building strengths in auto & engineering and ecommerce
...................................................................................................................................................................................................................................................................................................................................................
$TSLA: Awaiting Breakout - Is Tesla Ready to Surge?
Breakout Level: Awaiting breakout above $215.66
Resistance Levels:
First Resistance: $221.05
Second Resistance: $224.85
Third Resistance: $228.26
Watch Point: Tesla is nearing a key resistance level. A breakout above $215.66 could trigger a strong bullish move.
SBIN: Watch for Breakout - Bullish or Bearish?
Bullish Breakout Level: Above ₹832.15
Potential Upside: Targeting ₹899
Bearish Breakout Level: Below ₹794.75
Potential Downside: Targeting ₹731.10
Critical Juncture: The stock is at a key decision point. Monitor closely for a breakout in either direction to plan your trade.
SEQUENT SCIENTIFIC - Multi Year Breakout StockINVERSE HEAD & SHOULDER PATTERN BREAKOUT STOCK FOR SWING TRADING
> 2 Years of Inverse head & shoulder breakout
BUY PRICE : 155
SL : 125 (only for swing traders)
TARGET : 202, 250, 305 (100%)
Disclaimer - All information on this page is for educational purposes only,
we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you made.
Natco Pharma Breakout Retest! 🚀
Hey Dosto! 👋
🔍 Chart Analysis: Natco Pharma - CMP 980 📊
🚀 Reasons for Trade:
Strong Uptrend
Cup and Handle Breakout Retest
💹 Trade Details:
CMP: 980
SL: 918
Targets: 1090, 1188
🌟 Why Natco Pharma? After a cup and handle breakout, Natco Pharma has retraced for a retest, indicating potential upward momentum.
💡 Trade Strategy:
📈 Enter after retest confirmation.
⚖️ Set SL at 918.
🎯 Targets at 1050, 1110, and 1200.
📈 Disclaimer: I'm not a SEBI registered analyst. Trade at your own discretion.
🚀 Excited about this trade? Share your thoughts below! Let's discuss! 🤝💬
#NatcoPharma #StockMarket #TradeAlert #TechnicalAnalysis #BreakoutRetest 📈✨
NETWORK 18 - RANGE BREAKOUT FOR SWINGRANGE BREAKOUT FOR SWING TRADING
NEW BUY PRICE : 95
SL : 85 (only for swing traders)
TARGET : 120, 135 (40%)
Disclaimer - All information on this page is for educational purposes only, we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you made.
EVEREST KANTO CYLINDER - SWING TRADING STOCK 25/08/2024BREAKOUT STOCK FOR SWING TRADING
BUY PRICE : 183
SL : 150 (only for swing traders)
TARGET : 280 (50%)
Disclaimer - All information on this page is for educational purposes only,
we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you made.
ALKYLAMINE is Reacting & Showing Change in Structure & STORYNSE:ALKYLAMINE
............................................................................................................................................................................................................................................
TURN-AROUND STORY IS IN PROGRES IN TERMS OF PRODUCTION FACILITY AND SUSTAINABLE PRODUCT WHICH WILL BE ABLE COMPETE CHINESE COMPATETORS
............................................................................................................................................................................................................................................
Company has reduced debt.
Company is almost debt free.
Company has a good return on equity (ROE) track record: 3 Years ROE 19.0%.
Company has been maintaining a healthy dividend payout of 26.5%.
............................................................................................................................................................................................................................................
Strong financial risk profile and ample liquidity: Networth was healthy at Rs. 1263 crores as on March 31, 2024 (Rs 1165 crore as on March 31, 2023), with nil gearing as on March 31, 2024.The total outside liabilities to adjusted networth (TOL/ANW) ratio though had decreased to 0.25 time as on March 31, 2024 from 0.36 times as on March 31, 2023, and it is expected to improve over the medium term driven by steady accretion to reserves, absence of long term loans and moderate reliance on external debt for working capital and capex. Cash and cash equivalents of Rs 17 crore as on March 31, 2024, provide cushion to overall liquidity. Interest coverage ratio has improved to 60.4 times March 31, 2024. It is expected to remain healthy over the medium term.
............................................................................................................................................................................................................................................
KOPRAN Showed Breakout with Huge Volume at 52 Weeks High ZoneNSE:KOPRAN
The co. has set up a new API plant at Panoli, commercial production at this facility is expected to be started from Q3 FY25. In FY23, it completed upgradation and expansion of the multi-product plant at the Mahad facility for existing products and to manufacture new molecules.
An integrated Pharmaceutical Company, committed to supplying International
Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally.
State-of-the-art manufacturing facilities and products with various accreditations
and approvals by major global regulatory authorities.
The formulations vertical is operated through Kopran Limited.
The API vertical is being operated under Kopran Research Laboratories Ltd.
(KRLL), a wholly owned subsidiary of Kopran Limited